aTyr Pharma (NASDAQ:ATYR) Raised to “Hold” at Wall Street Zen

aTyr Pharma (NASDAQ:ATYR) was upgraded by Wall Street Zen to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings cut aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

aTyr Pharma Price Performance

ATYR stock opened at $4.94 on Friday. The business has a 50 day moving average price of $13.21 and a 200 day moving average price of $24.14. The stock has a market cap of $12.10 million, a price-to-earnings ratio of -0.20 and a beta of 1.05. aTyr Pharma has a fifty-two week low of $4.07 and a fifty-two week high of $44.40.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings results on Friday, August 7th. The company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.86) by $0.46. As a group, sell-side analysts anticipate that aTyr Pharma will post -17.80 EPS for the current year.

Institutional Investors Weigh In On aTyr Pharma

An institutional investor recently bought a new stake in aTyr Pharma stock. Renaissance Technologies LLC acquired a new position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 40,522 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.